Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash Items
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Beginning Cash Balance: 2023-2025

Historic Beginning Cash Balance for BioLineRx (BLRX) over the last 1 years, with Jun 2025 value amounting to -$1.1 million.

  • BioLineRx's Beginning Cash Balance fell 43.22% to -$1.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$15.1 million, marking a year-over-year decrease of 389.51%. This contributed to the annual value of -$14.4 million for FY2024, which is 835.39% down from last year.
  • BioLineRx's Beginning Cash Balance amounted to -$1.1 million in Q2 2025, which was down 0.00% from -$1.1 million recorded in Q1 2025.
  • In the past 5 years, BioLineRx's Beginning Cash Balance registered a high of -$741,000 during Q4 2023, and its lowest value of -$12.0 million during Q4 2024.
  • For the 3-year period, BioLineRx's Beginning Cash Balance averaged around -$2.3 million, with its median value being -$858,000 (2023).
  • Data for BioLineRx's Beginning Cash Balance shows a maximum YoY slumped of 1,515.65% (in 2024) over the last 5 years.
  • Over the past 3 years, BioLineRx's Beginning Cash Balance (Quarterly) stood at -$741,000 in 2023, then slumped by 1,515.65% to -$12.0 million in 2024, then slumped by 43.22% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q2 2025, -$1.1 million for Q1 2025, and -$12.0 million during Q4 2024.